APOEɛ4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease
- PMID: 33016906
- DOI: 10.3233/JAD-200556
APOEɛ4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease
Abstract
Background: Mild cognitive impairment (MCI) has been considered as a pre-dementia stage, although the factors leading to Alzheimer's disease (AD) conversion remain controversial.
Objective: Evaluate whether TOMM40 poly-T (TOMM40' 523) polymorphism is associated with the risk and conversion time from MCI to AD and secondly with AD cerebrospinal fluid (CSF) biomarkers, disentangling the APOE genotype.
Methods: 147 AD patients, 102 MCI patients, and 105 cognitively normal controls were genotyped for poly-T polymorphism. MCI patients were subdivided into two groups, the group of patients that converted to AD (MCI-AD) and the group of those that remained stable (MCI-S).
Results: TOMM40' 523 L allele was significantly more frequent in the MCI-AD group and having at least one L allele significantly increased the risk of conversion from MCI to AD (OR = 8.346, p < 0.001, 95% CI: 2.830 to 24.617). However, when adjusted for the presence of APOEɛ4 allele, both the L allele and ɛ4 allele lost significance in the model (p > 0.05). We then analyzed the APOEɛ4-TOMM40' 523 L haplotype and observed that patients carrying this haplotype had significantly higher risk (OR = 5.83; 95% CI = 2.30-14.83) and mean lower times of conversion to AD (p = 0.003). This haplotype was also significantly associated with a biomarker profile compatible with AD (p = 0.007).
Conclusion: This study shows that the APOEɛ4-TOMM40' 523 L haplotype is associated with a higher risk and shorter times of conversion from MCI to AD, possibly driven by CSF biomarkers and mitochondrial dysfunction.
Keywords: APOE; Age of onset; Alzheimer’s disease; TOMM40; biomarker; cerebrospinal fluid; haplotype; mild cognitive impairment; poly T; progression.
Similar articles
-
Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.J Alzheimers Dis. 2016 Jul 29;54(1):157-68. doi: 10.3233/JAD-160176. J Alzheimers Dis. 2016. PMID: 27472875
-
Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.J Alzheimers Dis. 2018;61(3):1097-1105. doi: 10.3233/JAD-170695. J Alzheimers Dis. 2018. PMID: 29254094
-
Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.J Alzheimers Dis. 2017;56(2):687-697. doi: 10.3233/JAD-151068. J Alzheimers Dis. 2017. PMID: 28035918
-
Cognitive Improvement After Multi-Domain Lifestyle Interventions in an APOE ɛ4 Homozygous Carrier with Mild Cognitive Impairment: A Case Report and Literature Review.J Alzheimers Dis. 2022;89(4):1131-1142. doi: 10.3233/JAD-220374. J Alzheimers Dis. 2022. PMID: 35988223 Review.
-
Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.Alzheimers Dement. 2015 Jul;11(7):792-814. doi: 10.1016/j.jalz.2015.05.009. Alzheimers Dement. 2015. PMID: 26194313 Free PMC article. Review.
Cited by
-
Untargeted urine metabolomics reveals dynamic metabolic differences and key biomarkers across different stages of Alzheimer's disease.Front Aging Neurosci. 2025 Jan 27;17:1530046. doi: 10.3389/fnagi.2025.1530046. eCollection 2025. Front Aging Neurosci. 2025. PMID: 39931229 Free PMC article.
-
Cell-type specific epigenetic clocks to quantify biological age at cell-type resolution.Aging (Albany NY). 2024 Dec 29;16(22):13452-13504. doi: 10.18632/aging.206184. Epub 2024 Dec 29. Aging (Albany NY). 2024. PMID: 39760516 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous